← Back to Search

Radiation Therapy

36.25Gy to prostate in 5 fractions for Prostate Cancer

Phase 4
Waitlist Available
Led By Albert DeNittis, MD
Research Sponsored by Albert DeNittis
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
histologically proven prostate adenocarcinoma within 1 year of enrollment
Low risk: Gleason <or=6 & PSA <or=10 & Clinical Stage T1b-T2a,Nx or N0, Mx or M0
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 years
Awards & highlights

Study Summary

This trial is testing a new cancer treatment to see if it is effective and has fewer side effects than the current standard of care.

Eligible Conditions
  • Prostate Cancer

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
acute and late GI/GU toxicity rate following treatment
Secondary outcome measures
a comparison of biochemical disease free survival in low risk patients treated with TrueBeam compared to (historical) biochemical disease free survival in patients treated with dose-escalated external beam radiation therapy

Trial Design

1Treatment groups
Experimental Treatment
Group I: 36.25Gy to prostate in 5 fractionsExperimental Treatment1 Intervention
36.25Gy to be delivered to the prostate in 5 fractions. There is only 1 arm in this study.

Find a Location

Who is running the clinical trial?

Albert DeNittisLead Sponsor
Albert DeNittis, MDPrincipal Investigator - Lankenau Medical Center, Main Line Health
Lankenau Medical Center, Main Line Health Imaging LP
Umdnj-Robt W Johnson Medical Sch (Medical School)
University Of Pa Hlth System (Residency)
1 Previous Clinical Trials
20 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Technology in Cancer Research & TreatmentJournal
Cyberknife Radiotherapy for Localized Prostate Cancer: Rationale and Technical Feasibility
King, Christopher R., Joerg Lehmann, John R. Adler, and Jenny Hai. 2003. “Cyberknife Radiotherapy for Localized Prostate Cancer: Rationale and Technical Feasibility”. Technology in Cancer Research & Treatment. SAGE Publications. doi:10.1177/153303460300200104.
clinicaltrials.govStudy
Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
Albert DeNittis 2011. "Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01581749.
~4 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top